Comprehensive ADME Overview Notes
Principles of Drug Absorption
Solubilization Requirements for Oral Absorption:
Solid dosage forms must dissolve into solution before systemic absorption can occur; the rate of dissolution often acts as the rate-limiting step for overall absorption.
Key physicochemical factors governing solubilization include degree of ionization (pH-dependent), molecular polar hydrophilicity, and overall molecular shape.
Polar molecules generally exhibit higher aqueous solubility, whereas non-polar lipophilic molecules exhibit higher membrane permeability.
Lipinski's Rule of 5:
Predicts that oral absorption is likely to be poor for a small molecule drug candidate if it violates more than one of the following thresholds:
There are more than hydrogen bond donors (calculated as the sum of all and functional groups).
There are more than hydrogen bond acceptors (calculated as the sum of all and atoms).
The molecular weight () is greater than .
The calculated octanol-water partition coefficient () is greater than .
Mechanisms of Membrane Transport:
Paracellular Diffusion: Movement between adjacent cells. Limited to small (), polar drugs. Permeability varies significantly across tissue types depending on tight junctions (e.g., nasal epithelium is relatively leaky, whereas GI tract epithelium is tighter, and the blood-brain barrier contains extremely tight junctions).
Passive Lipid Diffusion: Uncharged lipophilic drugs pass directly through the phospholipid membrane bilayer. Governed by Fick's Law of Diffusion:
* Passive permeability is governed by solubility in membrane lipid (lipid:water partition coefficient), charge/ionization state, mobility within membrane lipids (diffusion coefficient), and molecular mass (increased molecular mass reduces permeability).
* **The Absorption Conflict:** Polar drugs possess high aqueous solubility () but low membrane permeability, whereas lipophilic drugs possess high permeability () but low aqueous solubility. Both factors directly drive total absorption across intestinal transit time () and small intestine volume ().
pH Trapping and the pH Partition Hypothesis:
Uncharged (unionized) molecules preferentially cross lipid membranes via passive diffusion.
Weak acids () dissociate according to the equilibrium:
* Weak bases () protonate according to the equilibrium:
* In acidic environments (high ), weak carboxyl acids () remain unionized and lipophilic, whereas weak amines () become ionized (). In alkaline environments, weak acids ionize to carboxylates (), whereas weak bases remain uncharged free bases.
* Quantitative ionization ratios are calculated using the **Henderson-Hasselbalch Equations**:
* For weak acids:
* For weak bases:

Carrier-Mediated Transport & Specialized Pathways:
Can be active (energy-dependent, against a concentration gradient) or passive (facilitated diffusion).
Transporters exhibit structural specificity and saturability.
Critical for drug passage across the blood-brain barrier, gastrointestinal tract, renal tubules, biliary tract, and placenta.
Efflux Pumps: Efflux transporters such as P-glycoprotein (encoded by the gene) in intestinal mucosal membranes pump absorbed drug molecules back into the GI lumen, reducing bioavailability.
Aquaporins: Transmembrane protein channels responsible for transporting water and small uncharged solutes across biological membranes; central to water reabsorption in renal tubules.
Pinocytosis: Vesicular engulfment of fluid or macromolecular solutes across cell membranes.
Factors Regulating Gastrointestinal and Parenteral Absorption
Anatomical and Physiological GI Factors:
Stomach: Small absorptive surface area (), highly acidic (). High acidity can cause chemical hydrolysis of acid-labile drugs.
Small Intestine: Principal site of oral drug absorption due to a massive surface area ( provided by villi and microvilli), high blood flow, and high epithelial permeability. Average transit time is .
Large Intestine (Colon): Intermediate surface area, alkaline environment (), with long transit times ranging from .

Formulation & Chemical Binding Factors:
Chemical conversion into a lipophilic prodrug can bypass mucosal permeability barriers for highly polar drugs.
Chelation and binding to co-administered GI contents prevent absorption (e.g., binding of drugs to cholestyramine; chelation of tetracycline by polyvalent metal cations such as , , or ).
Gastric Emptying Rates:
Rapid gastric emptying accelerates drug delivery to the small intestine, increasing absorption rate.
Co-ingested food (especially high fat content) delays gastric emptying. Exception: Poorly soluble drugs exhibit enhanced absorption when taken with food due to prolonged residence time permitting complete dissolution.
Presystemic Metabolism & Efflux:
Drug degradation can occur via GI microflora, mucosal wall enzymes (Cytochrome P450 isoforms, Monoamine Oxidase), or hepatic first-pass metabolism via portal circulation.
Intestinal CYP3A4 activity can be inhibited by co-ingested substances (e.g., grapefruit juice), significantly elevating drug exposure.
Subcutaneous and Intramuscular Parenteral Sites:
Capillary endothelial walls are vastly more permeable than GI epithelial membranes, allowing polar compounds and macromolecules to readily reach capillary or lymphatic vessels.
Absorption rate is predominantly controlled by local tissue blood perfusion.
Mechanisms of Drug Distribution
Body Fluid Compartments:
Reversible transfer of drug between blood and body tissues occurs across distinct anatomical fluid volumes (% expressed relative to total body weight):
Plasma: of body weight
Interstitial Water: of body weight
Intracellular Water: of body weight
Adipose Tissue (Fat): of body weight
Transcellular Water: of body weight (includes cerebrospinal fluid [CSF], vitreous humor, peritoneal, pleural, synovial fluids, and GI secretions)

Plasma and Tissue Protein Binding:
Drugs exist in reversible equilibrium between bound and free (unbound) states in plasma.
Binding Partners:
Serum Albumin: Binds predominantly acidic drugs.
-Acid Glycoprotein: Binds predominantly basic drugs.
Lipoproteins: Bind neutral and highly lipophilic drugs.
Fraction Unbound ():
Only unbound free drug exerts pharmacodynamic activity and crosses vascular endothelial barriers into interstitial/intracellular compartments.
Rapid dissociation rates allow protein-bound drug to act as a dynamic reservoir; extremely slow or irreversible binding is functionally equivalent to elimination.
Blood-Brain Barrier (BBB) Architecture:
Brain capillary endothelial cells are joined by continuous tight junctions, surrounded by a basement membrane and astrocyte foot processes.
Hydrophilic or highly polar drugs are strictly excluded from the CNS unless recognized by specialized active transport systems (e.g., uptake mediated by amino acid transporters).

Rate-Limiting Steps in Distribution:
Perfusion-Limited Distribution: Occurs when biological membranes present negligible physical barriers (typical for highly lipophilic molecules). Distribution rate to specific tissues is governed directly by blood flow rate (rapid accumulation in highly perfused organs such as heart, kidneys, liver, and brain).
Permeability-Limited Distribution: Occurs when target membranes present significant permeability barriers (typical for polar or charged drugs and large biologics/antibodies). Distribution rate is constrained by membrane permeability rather than organ blood flow.
Pharmacokinetic Compartment Models:
One-Compartment Model: Assumes rapid, instantaneous distribution of drug throughout plasma and vascularly accessible tissues following intravenous administration, yielding a single exponential elimination slope.
Two-Compartment Model: Describes rapid initial distribution into a central compartment (plasma and highly vascularized organs) followed by slow equilibration into a peripheral compartment (e.g., muscle, adipose tissue).
Plasma concentration decay curves exhibit two distinct phases: a distribution phase governed by distribution rate constant , and a terminal elimination phase governed by elimination rate constant

Pathways of Biotransformation (Metabolism)
Overview and Physiological Rationale:
Primary objective: Chemically transform non-polar lipophilic compounds into polar, water-soluble metabolites to enable renal or biliary excretion.
Primary organ site: Liver (hepatocytes).
Overall elimination process: .
Phase I Reactions (Functionalization):
Introduces or unmasks polar functional groups (, , , ) via oxidation, reduction, or hydrolysis, increasing chemical reactivity for subsequent conjugation.
Cytochrome P450 (CYP) Monooxygenase System:
Responsible for of all Phase I oxidative biotransformations.
Heme-containing iron proteins switching between ferric () and ferrous () states.
Major human liver isoforms include CYP3A4 and CYP2D6, displaying broad, overlapping substrate specificities.
Exhibits high genetic polymorphism and susceptibility to competitive inhibition or enzyme induction by drugs and diet.
Cytochrome P450 Catalytic Cycle:
Ferric P450 () binds substrate drug ().
NADPH-P450 reductase / Cytochrome transfers an electron (), reducing iron to ferrous state ().
Molecular oxygen () binds to yield a complex.
Delivery of a second electron and proton () generates .
Loss of water () forms a reactive iron-oxoid intermediate .
Oxygen atom is inserted into drug substrate, releasing hydroxylated product () and regenerating ferric P450 ().

Non-CYP Phase I Enzymes:
Alcohol dehydrogenase, Monoamine oxidase (MAO), Carboxylesterases, Dehydrogenases, Oxidases, Reductases, and Glutathione -transferases (GST).
Phase II Reactions (Conjugation):
Couples a Phase I metabolite or parent drug with an endogenous hydrophilic moiety (e.g., glucuronic acid, glutathione, sulfate, acetate).
Conjugated metabolites are generally inactive, highly polar, non-reactive, and easily excreted.
Glucuronidation: Catalyzed by UDP-glucuronosyltransferases (UGT), utilizing UDP-glucuronic acid to form drug-glucuronides.
Glutathione Conjugation: Catalyzed by Glutathione -transferase (GST), transferring glutathione (tripeptide Cys-Glu-Gly with a free reactive thiol group) to electrophilic reactive drug intermediates, neutralizing potential cellular toxicity.
Mechanics of Drug Excretion
Excretion Overview:
Excretion is the irreversible physical elimination of unchanged drug or metabolites from the body.
Excretory routes: Urine (primary route), Bile (feces), Sweat, Exhaled breath, Breast milk.
Processes of Renal Excretion:
Total renal clearance is calculated as:

1. Glomerular Filtration:
Passive bulk flow through fenestrated glomerular capillaries in the renal corpuscle.
Normal Glomerular Filtration Rate (GFR): . Measured clinically using inulin or endogenous creatinine clearance.
Excludes molecules with molecular weight and plasma protein-bound drug fraction; only free unbound drug is filtered.
2. Active Tubular Secretion:
Active, carrier-mediated transport across proximal convoluted tubular cells.
Utilizes non-specific transport systems for organic anions (OATs) and organic cations (OCTs).
Saturable process subject to competitive drug inhibition. Transport carriers strip drug from plasma proteins as free concentration drops.
3. Tubular Reabsorption:
Endogenous nutrients (glucose, vitamins) are actively reabsorbed.
Drugs reabsorb predominantly via passive lipid diffusion across tubular epithelium back into peritubular capillaries.
Extremely sensitive to lipophilicity and urinary pH (ion trapping). Alkalinization of urine forces weak acid drugs (e.g., aspirin, ) into ionized conjugate forms (), blocking reabsorption and enhancing urinary clearance. Acidification of urine forces weak bases (e.g., pethidine, ) into protonated forms (), driving excretion.
Biliary Excretion and Enterohepatic Recirculation:
Active carrier secretion by hepatocytes into bile canaliculi.
Favors polar compounds with molecular weight (especially glucuronide conjugates).
Enterohepatic Recirculation: Secreted drug-glucuronides enter the duodenum via the bile duct. Intestinal microflora express enzymes (such as -glucuronidase) that cleave the glucuronide moiety, releasing free, lipophilic parent drug. The liberated drug is reabsorbed across intestinal mucosa into the portal vein back to the liver, forming a persistent recirculating loop that significantly prolongs terminal elimination half-life.

Principles of Drug Absorption
Solubilization Requirements for Oral Absorption:
Solid dosage forms must dissolve into solution before systemic absorption can occur; the rate of dissolution often acts as the rate-limiting step for overall absorption.
Key physicochemical factors governing solubilization include degree of ionization (pH-dependent), molecular polar hydrophilicity, and overall molecular shape.
Polar molecules generally exhibit higher aqueous solubility, whereas non-polar lipophilic molecules exhibit higher membrane permeability.
Lipinski's Rule of 5:
Predicts that oral absorption is likely to be poor for a small molecule drug candidate if it violates more than one of the following thresholds:
There are more than hydrogen bond donors (calculated as the sum of all and functional groups).
There are more than hydrogen bond acceptors (calculated as the sum of all and atoms).
The molecular weight () is greater than .
The calculated octanol-water partition coefficient () is greater than 5$.
Mechanisms of Membrane Transport (Diagram Breakdown):
Membrane Transport Routes Diagram:
Paracellular Diffusion: Movement between adjacent cells, limited to small (M_r < 350\,\text{g/mol}\text{Flux} = \frac{(C1 - C2) \times \text{Area} \times \text{Permeability}}{\text{Thickness}}C1 - C2\text{AH}\text{B}\text{A}^-\text{BH}^+\text{AH} \rightleftharpoons \text{A}^- + \text{H}^+\text{BH}^+ \rightleftharpoons \text{B} + \text{H}^+
Carrier-Mediated & Efflux Transport Diagram:
Explanation: Shows uptake transporters facilitating drug entry into blood/tissues, contrasted with efflux pumps (e.g., P-glycoprotein encoded by \text{MDR1}\sim 1\,\text{m}^2\sim 200\,\text{m}^210\text{--}36\,\text{hours}).
Transit Time & Formulation Factors:
Gastric emptying rate determines transit speed to the small intestine; delay by food (especially lipids) provides additional time for poorly soluble drugs to dissolve.
Binding interactions (e.g., tetracycline chelating with divalent metal ions \text{M}^{2+}5\%16\%35\%20\%2\%\ln[\text{Drug}]\alpha\beta\text{CYP3A4}M_r < 20{,}000\,\text{g/mol}\text{Renal Excretion} = \text{Filtration} + \text{Secretion} - \text{Reabsorption}
Biliary Excretion & Enterohepatic Recycling Diagram:
Explanation: Active secretion of polar, higher molecular weight (M_r > 350\,\text{g/mol}$$) compounds from liver into bile duct and gallbladder. Once delivered to the small intestine, conjugated drug can be hydrolyzed by gut flora and reabsorbed via the portal vein back to the liver, establishing a recycling loop.